SI-BONE (SIBN) Scheduled to Post Earnings on Monday

SI-BONE (NASDAQ:SIBN) is set to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Monday, February 26th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $38.86 million during the quarter, compared to analysts’ expectations of $38.60 million. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Trading Down 2.8 %

SI-BONE stock opened at $14.20 on Friday. SI-BONE has a 12-month low of $14.07 and a 12-month high of $29.51. The firm has a market capitalization of $585.10 million, a price-to-earnings ratio of -12.46 and a beta of 1.24. The firm has a 50 day moving average of $15.99 and a 200 day moving average of $18.03. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21.

Analysts Set New Price Targets

SIBN has been the subject of a number of recent research reports. Piper Sandler initiated coverage on shares of SI-BONE in a report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Truist Financial restated a “buy” rating and issued a $24.00 price objective (down from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Morgan Stanley upped their target price on SI-BONE from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $27.00 target price on shares of SI-BONE in a report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $26.67.

Insider Buying and Selling at SI-BONE

In other news, Director Mika Nishimura sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total value of $40,550.00. Following the completion of the sale, the director now directly owns 19,350 shares in the company, valued at $313,857. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the business’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the transaction, the chief financial officer now owns 205,516 shares of the company’s stock, valued at $3,175,222.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mika Nishimura sold 2,500 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total transaction of $40,550.00. Following the completion of the sale, the director now directly owns 19,350 shares of the company’s stock, valued at approximately $313,857. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,905 shares of company stock valued at $190,273. 5.40% of the stock is owned by insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.